Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Evans

Showing results (71-80 of 208) with videos related to

Pageof 21
Sort By:
Molecular Cancer Therapeutics|October 30, 2016
Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate CancerChengfei Liu, Cameron M Armstrong, Wei Lou, et al.
Molecular Cancer Therapeutics|February 26, 2009
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2Siting Feng, Qizhu Tang, Meng Sun, et al.
The Journal of Urology|October 20, 2012
CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growthHiromi Inoue, Michael Kauffman, Sharon Shacham, et al.
The Journal of Urology|May 6, 2004
The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan dataDavid F Penson, Judd W Moul, Christopher P Evans, et al.
European Urology|April 29, 2008
Current applications for prostate-specific antigen doubling timeMichelle L Ramírez, Eric C Nelson, Ralph W Devere White, et al.
Molecular Cancer Therapeutics|May 24, 2013
NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variantsNagalakshmi Nadiminty, Ramakumar Tummala, Chengfei Liu, et al.
European Urology Focus|September 18, 2023
Secondary Bladder Cancer After Prostate Cancer Treatment: An Age-matched Comparison Between Radiation and SurgerySteven Monda, Manolis Pratsinis, Hansen Lui, et al.
Cancer|November 22, 2013
No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year periodJennifer N Wu, Kari M Fish, Christopher P Evans, et al.
The Prostate|May 10, 2017
MicroRNA-181a promotes docetaxel resistance in prostate cancer cellsCameron M Armstrong, Chengfei Liu, Wei Lou, et al.
The Journal of Urology|April 18, 2009
Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004Nicholas J Hellenthal, Michelle L Ramírez, Christopher P Evans, et al.
Pageof 21

Showing results (71-80 of 208) with videos related to

Sort By:
Pageof 21
Molecular Cancer Therapeutics|October 30, 2016
Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate CancerChengfei Liu, Cameron M Armstrong, Wei Lou, et al.
Molecular Cancer Therapeutics|February 26, 2009
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2Siting Feng, Qizhu Tang, Meng Sun, et al.
The Journal of Urology|October 20, 2012
CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growthHiromi Inoue, Michael Kauffman, Sharon Shacham, et al.
The Journal of Urology|May 6, 2004
The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan dataDavid F Penson, Judd W Moul, Christopher P Evans, et al.
European Urology|April 29, 2008
Current applications for prostate-specific antigen doubling timeMichelle L Ramírez, Eric C Nelson, Ralph W Devere White, et al.
Molecular Cancer Therapeutics|May 24, 2013
NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variantsNagalakshmi Nadiminty, Ramakumar Tummala, Chengfei Liu, et al.
European Urology Focus|September 18, 2023
Secondary Bladder Cancer After Prostate Cancer Treatment: An Age-matched Comparison Between Radiation and SurgerySteven Monda, Manolis Pratsinis, Hansen Lui, et al.
Cancer|November 22, 2013
No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year periodJennifer N Wu, Kari M Fish, Christopher P Evans, et al.
The Prostate|May 10, 2017
MicroRNA-181a promotes docetaxel resistance in prostate cancer cellsCameron M Armstrong, Chengfei Liu, Wei Lou, et al.
The Journal of Urology|April 18, 2009
Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004Nicholas J Hellenthal, Michelle L Ramírez, Christopher P Evans, et al.
Pageof 21